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CLINICAL PATHOLOGIC CHALLENGE ANSWER

An Elderly Male With Progressive Nail Atrophy: Answer
Ogochukwu Nefertiti Umeh, BS, MS,* Ryan Beekman, MD,† Helen D’sa, DO,‡
and Ben J. Friedman, MD§¶

(Am J Dermatopathol 2021;43:152–153)

(Continued from page e20)

ANSWER
Systemic light-chain amyloidosis (AL).

DISCUSSION
Histopathological examination of the nail bed revealed
a pink amorphous material surrounding blood vessels in the
dermis (Figure 2 in the Question portion). A Congo red stain
highlighted the material (Fig. 3), which also demonstrated faint
green-yellow birefringence on polarization (not shown). Immunohistochemistry for lambda light chains was positive (Fig. 4),
whereas there was no staining for kappa. A previously obtained
gastric biopsy from 6 months before was revisited and was also
found to demonstrate amyloid on Congo red staining.
Given these pathologic ﬁndings combined with the
patient’s constellation of symptoms, a diagnosis of immunoglobulin light-chain (AL) amyloidosis was strongly suspected and a thorough systemic workup was recommended.
A serum protein electrophoresis study was obtained and revealed
a small free lambda monoclonal protein (,0.1 g/dL) with

marked suppression of polyclonal gammaglobulin. A free
serum light chain analysis revealed a lambda level of
2686.0 (normal range: 5.7–26.3 mg/L). A subsequent bone
marrow biopsy revealed atypical plasma cells occupying
25% of the marrow space consistent with plasma cell
myeloma.
The patient was treated with 3 cycles of bortezomib,
cyclophosphamide, and dexamethasone (CyBorD) with poor
response and disease progression. He was not eligible for
stem cell transplant due to severe amyloid-included restrictive
cardiomyopathy complicated by worsening congestive heart
failure. Three months after his diagnosis, he was admitted to
hospice for comfort measures.
AL amyloidosis is a paraneoplastic phenomenon characterized by deposition of misfolded proteins in various
organs. The most commonly affected organs include the
heart, kidneys, liver, soft tissues, peripheral and/or autonomic
nervous system, and gastrointestinal tract.1,2 It is associated
with an underlying plasma cell dyscrasia, usually multiple

FIGURE 3. Congo red stain (original magnification, ·400).

From the *St. George’s University School of Medicine, Grenada, West Indies;
†Departments of Orthopedics, ‡Dermatology, Henry Ford Allegiance
Health, and §Department of Dermatology, Henry Ford Health System,
Detroit, MI; and ¶Department of Pathology, Laboratory Medicine, Henry
Ford Health System, Detroit, MI.
The authors declare no conﬂicts of interest.
Correspondence: Ben J. Friedman, MD, 3031 West Grand Blvd, Ste 800,
Detroit, MI 48202 (e-mail: bfriedm1@hfhs.org).
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

FIGURE 4. A, Lambda immunohistochemical stain (original
magnification, ·400). B, Kappa immunohistochemical stain
(original magnification, ·400).
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myeloma. Often, the myeloma is diagnosed subsequent to the
amyloid-induced systemic complications, as seen in our case.
Presenting symptoms of systemic AL amyloidosis are broad
and may mimic other more common diseases seen in elderly
patients and unfortunately this can promote diagnostic delay.
Mucocutaneous involvement in systemic AL amyloidosis occurs in one-third of patients including those with the
myeloma-associated form and is rarely the initial manifestation.2–5 Commonly reported ﬁndings are periorbital “pinch”
purpura and macroglossia. Sporadic cases of AL amyloidosis
presenting as 20 nail dystrophy have also been reported.3–5
Dermatologists and dermatopathologists must be aware of
this association because they may be relied upon to make
an earlier diagnosis. Optimal treatment is controversial with
poor outcomes overall. High-dose steroids, chemotherapeutic
regimens including bortezomib-based regimens or melphalan,
and stem cell transplantation are among the modalities typically used.6–8

1. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging
system for light chain amyloidosis incorporating cardiac biomarkers and
serum free light chain measurements. J Clin Oncol. 2012;30:989–995.
2. Li G, Han D, Wei S, et al. Multiorgan involvement by amyloid light chain
amyloidosis. J Int Med Res. 2019;47:1778–1786.
3. Xu J, Tahan S, Jan F, et al. Nail dystrophy as the initial sign of multiple
myeloma-associated systemic amyloidosis. J Cutan Pathol. 2016;43:543–545.
4. Fanti PA, Tosti A, Morelli R, et al. Nail changes as the ﬁrst sign of
systemic amyloidosis. Dermatologica. 1991;183:44–46.
5. Fujita Y, Tsuji-Abe Y, Sato-Matsumura KC, et al. Nail dystrophy and
blisters as sole manifestations in myeloma-associated amyloidosis. J Am
Acad Dermatol. 2006;54:712–714.
6. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new
therapeutic options. J Clin Oncol. 2011;29:1924–1933.
7. Zumbo G, Sadeghi-Alavijeh O, Hawkins PN, et al. New and Developing
therapies for AL amyloidosis. Expert Opin Pharmacother. 2017;18:139–149.
8. Dispenzieri A, Buadi F, Kumar SK, et al Treatment of immunoglobulin
light chain amyloidosis: mayo stratiﬁcation of myeloma and risk-adapted
therapy (mSMART) consensus statement. Mayo Clin Proc. 2015;90:
1054–81.

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

REFERENCES

www.amjdermatopathology.com |

153

Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

